Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för Todd E Simpson. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att Todd E Simpson har rapporterat innehav eller affärer i följande företag:
Värdepapper | Titel | Senaste rapporterade innehav |
---|---|---|
US:XNCR / Xencor, Inc. | Director | 13 686 |
US:SGEN / Seagen Inc | Chief Financial Officer | 0 |
US:NLTX / Neoleukin Therapeutics, Inc. | Director | 25 000 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av Todd E Simpson. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderköp XNCR / Xencor, Inc. - Analys av kortsiktig vinst
I det här avsnittet analyserar vi lönsamheten för varje oplanerat insiderköp på en öppen marknad som görs i XNCR / Xencor, Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormal avkastning och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste öppna marknadsköpen som inte var en del av en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till max |
Pris vid max |
Max vinst ($) |
Maximal avkastning (%) |
---|---|---|---|---|---|---|---|
Det finns inga kända oplanerade öppna marknadstransaktioner för denna insider |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderförsäljning - Analys av kortsiktig förlust
I det här avsnittet analyserar vi det kortsiktiga undvikandet av förluster för varje oplanerad insiderförsäljning på öppen marknad som görs i XNCR / Xencor, Inc.. Ett konsekvent mönster för att undvika förluster kan tyda på att framtida försäljningstransaktioner kan förutsäga prisnedgångar. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Följande tabell visar de senaste försäljningarna på den öppna marknaden som inte ingick i en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till min |
Pris vid min |
Maximal förlust undvikits ($) |
Maximal förlust undvikits ($) |
---|---|---|---|---|---|---|---|
Det finns inga kända oplanerade öppna marknadstransaktioner för denna insider |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av Todd E Simpson som avslöjats för Securities Exchange Commission (SEC).
Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-06-16 |
|
4 | XNCR |
Xencor Inc
Common Stock |
A - Award | 13 686 | 13 686 | |||||
2023-12-15 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
D - Sale to Issuer | −93 292 | 0 | −100,00 | 229,00 | −21 363 868 | ||
2023-09-22 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −80 | 128 723 | −0,06 | 206,50 | −16 520 | 26 581 300 |
2023-09-01 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −2 122 | 128 803 | −1,62 | 206,97 | −439 182 | 26 657 829 |
2023-08-30 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −485 | 130 925 | −0,37 | 206,00 | −99 910 | 26 970 550 |
2023-08-30 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
A - Award | 1 225 | 131 410 | 0,94 | ||||
2023-08-17 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
D - Sale to Issuer | X | −1 540 | 130 185 | −1,17 | 193,87 | −298 558 | 25 238 823 |
2023-08-17 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
D - Sale to Issuer | X | −861 | 131 725 | −0,65 | 193,87 | −166 921 | 25 537 381 |
2023-08-17 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
D - Sale to Issuer | X | −1 106 | 132 586 | −0,83 | 193,87 | −214 419 | 25 704 302 |
2023-08-17 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
A - Award | 14 746 | 133 692 | 12,40 | ||||
2023-04-12 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −40 364 | 118 946 | −25,34 | 204,74 | −8 264 125 | 24 353 004 |
2023-04-12 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 40 364 | 159 310 | 33,93 | 46,37 | 1 871 679 | 7 387 205 | |
2023-04-12 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −14 980 | 118 946 | −11,19 | 204,14 | −3 058 017 | 24 281 636 |
2023-04-12 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 14 980 | 133 926 | 12,59 | 46,37 | 694 623 | 6 210 149 | |
2023-04-07 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −243 | 118 946 | −0,20 | 205,86 | −50 023 | 24 485 819 |
2023-04-07 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
A - Award | 609 | 119 189 | 0,51 | ||||
2023-04-04 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
A - Award | 1 395 | 118 580 | 1,19 | ||||
2023-03-10 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −6 082 | 117 185 | −4,93 | 177,37 | −1 078 764 | 20 785 103 |
2023-03-10 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −26 449 | 123 267 | −17,67 | 176,71 | −4 673 803 | 21 782 512 |
2023-03-10 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −10 262 | 149 716 | −6,41 | 175,89 | −1 804 983 | 26 333 547 |
2023-03-10 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 42 793 | 159 978 | 36,52 | 45,30 | 1 938 523 | 7 247 003 | |
2023-02-28 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −20 000 | 117 185 | −14,58 | 182,53 | −3 650 600 | 21 389 778 |
2023-02-21 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −39 946 | 137 185 | −22,55 | 160,00 | −6 391 400 | 21 949 737 |
2023-02-21 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 39 946 | 177 131 | 29,12 | 39,15 | 1 563 886 | 6 934 679 | |
2022-09-01 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −2 064 | 137 185 | −1,48 | 154,41 | −318 712 | 21 183 353 |
2022-09-01 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −2 122 | 139 249 | −1,50 | 154,41 | −327 668 | 21 502 065 |
2022-08-17 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −1 106 | 141 371 | −0,78 | 170,22 | −188 258 | 24 063 479 |
2022-08-17 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −861 | 142 477 | −0,60 | 170,22 | −146 555 | 24 251 737 |
2022-08-17 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
A - Award | 15 447 | 143 338 | 12,08 | ||||
2022-05-16 |
|
4 | NLTX |
Neoleukin Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 25 000 | 25 000 | |||||
2022-04-22 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −567 | 127 891 | −0,44 | 144,32 | −81 829 | 18 457 050 |
2021-12-22 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −345 | 128 458 | −0,27 | 149,85 | −51 698 | 19 249 431 |
2021-11-05 |
|
4 | SGEN |
Seagen Inc.
Incentive Stock Option (right to buy) |
M - Exercise | −2 156 | 0 | −100,00 | ||||
2021-11-05 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 2 156 | 128 803 | 1,70 | 46,37 | 99 974 | 5 972 595 | |
2021-11-05 |
|
4 | SGEN |
Seagen Inc.
Non-Qualified Stock Option (right to buy) |
M - Exercise | −40 232 | 0 | −100,00 | ||||
2021-11-05 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −40 232 | 126 647 | −24,11 | 185,00 | −7 442 920 | 23 429 695 |
2021-11-05 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 40 232 | 166 879 | 31,77 | 44,09 | 1 773 829 | 7 357 695 | |
2021-11-02 |
|
4 | SGEN |
Seagen Inc.
Non-Qualified Stock Option (right to buy) |
M - Exercise | −33 564 | 0 | −100,00 | ||||
2021-11-02 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −33 564 | 126 647 | −20,95 | 180,00 | −6 041 523 | 22 796 473 |
2021-11-02 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 33 564 | 160 211 | 26,50 | 41,04 | 1 377 467 | 6 575 059 | |
2021-09-27 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
A - Award | 201 | 126 647 | 0,16 | 166,22 | 33 410 | 21 051 264 | |
2021-09-02 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −2 122 | 126 446 | −1,65 | 167,52 | −355 468 | 21 181 665 |
2021-09-02 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −1 865 | 128 568 | −1,43 | 167,52 | −312 416 | 21 537 133 |
2021-08-18 |
|
4 | SGEN |
Seagen Inc.
Non-Qualified Stock Option (right to buy) |
A - Award | 26 427 | 26 427 | |||||
2021-08-18 |
|
4 | SGEN |
Seagen Inc.
Incentive Stock Option (right to buy) |
A - Award | 642 | 642 | |||||
2021-08-18 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
A - Award | 11 095 | 130 433 | 9,30 | ||||
2021-08-18 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −533 | 119 338 | −0,44 | 154,55 | −82 377 | 18 444 165 |
2021-05-13 |
|
4 | NLTX |
Neoleukin Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 25 000 | 25 000 | |||||
2020-12-18 |
|
4 | SGEN |
Seagen Inc.
Non-Qualified Stock Option (right to buy) |
M - Exercise | −33 669 | 0 | −100,00 | ||||
2020-12-18 |
|
4 | SGEN |
Seagen Inc.
Incentive Stock Option (right to buy) |
M - Exercise | −1 104 | 0 | −100,00 | ||||
2020-12-18 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 1 104 | 119 871 | 0,93 | 45,30 | 50 011 | 5 430 156 | |
2020-12-18 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −33 669 | 118 767 | −22,09 | 200,00 | −6 733 800 | 23 753 400 |
2020-12-18 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 33 669 | 152 436 | 28,35 | 26,10 | 878 761 | 3 978 580 | |
2020-11-09 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | −7 509 | 118 767 | −5,95 | 180,37 | −1 354 383 | 21 421 766 | |
2020-09-02 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −469 | 126 276 | −0,37 | 159,33 | −74 726 | 20 119 555 |
2020-09-02 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −50 | 126 745 | −0,04 | 157,82 | −7 891 | 20 002 896 |
2020-09-02 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −1 640 | 126 795 | −1,28 | 156,87 | −257 267 | 19 890 332 |
2020-09-02 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −5 480 | 128 435 | −4,09 | 155,74 | −853 455 | 20 002 467 |
2020-09-02 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −4 452 | 133 915 | −3,22 | 155,25 | −691 173 | 20 790 304 |
2020-09-02 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −2 122 | 138 367 | −1,51 | 155,69 | −330 383 | 21 542 939 |
2020-09-02 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −2 065 | 140 489 | −1,45 | 155,69 | −321 509 | 21 873 322 |
2020-08-20 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −9 262 | 142 554 | −6,10 | 158,17 | −1 464 959 | 22 547 595 |
2020-08-17 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 20 774 | 20 774 | |||||
2020-08-17 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
A - Award | 636 | 636 | |||||
2020-08-17 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 8 635 | 151 816 | 6,03 | ||||
2020-08-05 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −1 905 | 143 181 | −1,31 | 166,74 | −317 640 | 23 874 000 |
2020-08-05 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −10 375 | 145 086 | −6,67 | 166,10 | −1 723 288 | 24 098 785 |
2020-08-05 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −7 720 | 155 461 | −4,73 | 164,96 | −1 273 491 | 25 644 847 |
2020-07-02 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −1 010 | 163 181 | −0,62 | 171,39 | −173 104 | 27 967 592 |
2020-07-02 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −139 | 164 191 | −0,08 | 170,18 | −23 655 | 27 942 024 |
2020-07-02 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −5 012 | 164 330 | −2,96 | 167,66 | −840 312 | 27 551 568 |
2020-07-02 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −4 112 | 169 342 | −2,37 | 166,99 | −686 663 | 28 278 421 |
2020-07-02 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −1 300 | 173 454 | −0,74 | 165,86 | −215 618 | 28 769 080 |
2020-05-07 |
|
4 | NLTX |
Neoleukin Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 25 000 | 25 000 | |||||
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −26 867 | 0 | −100,00 | ||||
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
M - Exercise | −1 103 | 0 | −100,00 | ||||
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
M - Exercise | −2 268 | 0 | −100,00 | ||||
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
M - Exercise | −2 436 | 0 | −100,00 | ||||
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
M - Exercise | −2 554 | 0 | −100,00 | ||||
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
M - Exercise | −3 831 | 0 | −100,00 | ||||
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 3 831 | 173 888 | 2,25 | 26,10 | 99 989 | 4 538 477 | |
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 2 436 | 170 057 | 1,45 | 41,04 | 99 973 | 6 979 139 | |
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 2 268 | 167 621 | 1,37 | 44,09 | 99 996 | 7 390 410 | |
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 2 554 | 165 353 | 1,57 | 39,15 | 99 989 | 6 473 570 | |
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 1 103 | 162 799 | 0,68 | 45,30 | 49 966 | 7 374 795 | |
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −1 200 | 161 696 | −0,74 | 164,10 | −196 920 | 26 534 314 | |
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −12 167 | 162 896 | −6,95 | 163,36 | −1 987 601 | 26 610 691 | |
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −13 500 | 175 063 | −7,16 | 162,45 | −2 193 075 | 28 438 984 | |
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 26 867 | 188 563 | 16,62 | 15,46 | 415 364 | 2 915 184 | |
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −14 167 | 0 | −100,00 | ||||
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −14 167 | 161 696 | −8,06 | 147,00 | −2 082 556 | 23 769 393 | |
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 14 167 | 175 863 | 8,76 | 12,00 | 170 004 | 2 110 356 | |
2020-04-21 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
D - Sale to Issuer | X | −570 | 161 696 | −0,35 | 139,92 | −79 752 | 22 623 906 |
2020-04-21 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 1 439 | 162 266 | 0,89 | ||||
2020-04-21 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 2 389 | 160 827 | 1,51 | ||||
2019-12-23 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 871 | 158 438 | 0,55 | ||||
2019-10-15 |
|
4 | NLTX |
Neoleukin Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 22 000 | 22 000 | |||||
2019-10-02 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −15 000 | 157 567 | −8,69 | 85,00 | −1 275 000 | 13 393 195 |
2019-09-04 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −2 092 | 172 567 | −1,20 | 70,80 | −148 112 | 12 217 623 |
2019-09-04 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 49 232 | 49 232 | |||||
2019-09-04 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
A - Award | 1 333 | 1 333 | |||||
2019-09-04 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 21 288 | 174 659 | 13,88 | ||||
2019-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −5 909 | 153 371 | −3,71 | 73,21 | −432 624 | 11 228 966 |
2019-08-22 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −12 500 | 159 280 | −7,28 | 80,00 | −1 000 000 | 12 742 400 |
2019-04-09 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −10 437 | 171 780 | −5,73 | 78,00 | −814 086 | 13 398 840 |
2019-04-09 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −2 063 | 182 217 | −1,12 | 78,00 | −160 914 | 14 212 926 |
2019-03-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −10 000 | 184 280 | −5,15 | 75,00 | −750 000 | 13 821 000 |
2018-09-04 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 47 904 | 47 904 | |||||
2018-09-04 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
A - Award | 1 301 | 1 301 | |||||
2018-09-04 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 20 715 | 194 280 | 11,94 | ||||
2018-08-29 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −5 427 | 173 565 | −3,03 | 74,23 | −402 856 | 12 884 042 |
2018-05-09 |
|
4 | AQXP |
AQUINOX PHARMACEUTICALS, INC
Stock Option (Right to Buy) |
A - Award | 15 000 | 15 000 | |||||
2018-03-22 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-qualified Stock Option (Right to buy) |
A - Award | 10 526 | 10 526 | |||||
2017-11-03 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −534 | 178 992 | −0,30 | 61,59 | −32 889 | 11 024 117 |
2017-11-03 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −38 851 | 179 526 | −17,79 | 60,90 | −2 366 026 | 10 933 133 |
2017-09-08 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −9 638 | 218 377 | −4,23 | 52,00 | −501 176 | 11 355 604 | |
2017-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −4 937 | 228 015 | −2,12 | 47,89 | −236 455 | 10 920 664 |
2017-08-18 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 55 344 | 55 344 | |||||
2017-08-18 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
A - Award | 2 156 | 2 156 | |||||
2017-08-18 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 23 000 | 232 952 | 10,95 | ||||
2017-05-10 |
|
4 | AQXP |
AQUINOX PHARMACEUTICALS, INC
Stock Option (Right to Buy) |
A - Award | 9 000 | 9 000 | |||||
2016-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 42 793 | 42 793 | |||||
2016-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
A - Award | 2 207 | 2 207 | |||||
2016-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 18 000 | 209 445 | 9,40 | ||||
2016-08-22 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −3 991 | 191 445 | −2,04 | 46,59 | −185 943 | 8 919 557 |
2016-05-11 |
|
4 | AQXP |
AQUINOX PHARMACEUTICALS, INC
Stock Option (Right to Buy) |
A - Award | 7 500 | 7 500 | |||||
2015-10-01 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
M - Exercise | −6 468 | 0 | −100,00 | ||||
2015-10-01 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
M - Exercise | −8 333 | 0 | −100,00 | ||||
2015-10-01 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 8 333 | 194 675 | 4,47 | 12,00 | 99 996 | 2 336 100 | |
2015-10-01 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 6 468 | 186 342 | 3,60 | 15,46 | 99 995 | 2 880 847 | |
2015-08-25 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 39 946 | 39 946 | |||||
2015-08-25 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
A - Award | 2 554 | 2 554 | |||||
2015-08-25 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 17 000 | 179 874 | 10,44 | ||||
2015-08-25 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −5 825 | 162 874 | −3,45 | 42,02 | −244 794 | 6 844 731 |
2015-03-16 |
|
4 | AQXP |
AQUINOX PHARMACEUTICALS, INC
Stock Option (Right to Buy) |
A - Award | 5 000 | 5 000 | |||||
2014-08-27 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 40 232 | 40 232 | |||||
2014-08-27 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
A - Award | 2 268 | 2 268 | |||||
2014-08-27 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 17 000 | 168 699 | 11,21 | ||||
2014-08-27 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −3 696 | 151 699 | −2,38 | 43,55 | −160 957 | 6 606 340 | |
2014-03-10 |
|
4 | AQXP |
AQUINOX PHARMACEUTICALS, INC
Stock Option (Right to Buy) |
A - Award | 8 333 | 8 333 | |||||
2014-03-06 | 3 | AQXP |
AQUINOX PHARMACEUTICALS, INC
No securities are beneficially owned |
0 | ||||||||
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
M - Exercise | −8 223 | 0 | −100,00 | ||||
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
M - Exercise | −9 017 | 0 | −100,00 | ||||
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
M - Exercise | −13 126 | 0 | −100,00 | ||||
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 8 223 | 155 395 | 5,59 | 12,16 | 99 992 | 1 889 603 | |
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 9 017 | 147 172 | 6,53 | 11,09 | 99 999 | 1 632 137 | |
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 13 126 | 138 155 | 10,50 | 10,29 | 135 067 | 1 421 615 | |
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −12 500 | 21 169 | −37,13 | ||||
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −12 500 | 21 169 | −37,13 | ||||
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −4 166 | 26 867 | −13,42 | ||||
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −2 972 | 0 | −100,00 | ||||
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −5 625 | 14 167 | −28,42 | ||||
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −12 500 | 125 029 | −9,09 | 41,45 | −518 095 | 5 182 152 | |
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −12 500 | 125 029 | −9,09 | 41,45 | −518 095 | 5 182 152 | |
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 12 500 | 137 529 | 10,00 | 26,10 | 326 250 | 3 589 507 | |
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 12 500 | 137 529 | 10,00 | 26,10 | 326 250 | 3 589 507 | |
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −4 166 | 125 029 | −3,22 | 41,45 | −172 671 | 5 182 152 | |
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 4 166 | 129 195 | 3,33 | 15,46 | 64 406 | 1 997 355 | |
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −5 625 | 125 029 | −4,31 | 41,45 | −233 143 | 5 182 152 | |
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 5 625 | 130 654 | 4,50 | 12,00 | 67 500 | 1 567 848 | |
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −2 972 | 125 029 | −2,32 | 41,45 | −123 182 | 5 182 152 | |
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 2 972 | 128 001 | 2,38 | 12,16 | 36 140 | 1 556 492 | |
2013-08-21 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 33 564 | 33 564 | 41,04 | 1 377 467 | 1 377 467 | ||
2013-08-21 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
A - Award | 2 436 | 2 436 | 41,04 | 99 973 | 99 973 | ||
2013-08-21 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 14 400 | 125 029 | 13,02 | ||||
2013-08-21 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −3 328 | 110 629 | −2,92 | 40,91 | −136 148 | 4 525 832 |
2013-07-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −29 166 | 31 033 | −48,45 | ||||
2013-07-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −18 361 | 19 792 | −48,12 | ||||
2013-07-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −29 166 | 113 957 | −20,38 | 37,94 | −1 106 558 | 4 323 529 |
2013-07-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 29 166 | 143 123 | 25,59 | 15,46 | 450 906 | 2 212 682 | |
2013-07-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −18 361 | 113 957 | −13,88 | 37,94 | −696 616 | 4 323 529 |
2013-07-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 18 361 | 132 318 | 16,11 | 12,00 | 220 332 | 1 587 816 | |
2013-07-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −1 486 | 2 972 | −33,33 | ||||
2013-07-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −43 514 | 38 153 | −53,28 | ||||
2013-07-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −43 514 | 113 957 | −27,63 | 36,94 | −1 607 407 | 4 209 572 |
2013-07-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 43 514 | 157 471 | 38,18 | 12,00 | 522 168 | 1 889 652 | |
2013-07-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −1 486 | 113 957 | −1,29 | 36,94 | −54 893 | 4 209 572 |
2013-07-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 1 486 | 115 443 | 1,30 | 12,16 | 18 070 | 1 403 787 | |
2013-03-08 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −19 494 | 4 458 | −81,39 | ||||
2013-03-08 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −682 | 0 | −100,00 | ||||
2013-03-08 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −19 494 | 113 957 | −14,61 | 30,70 | −598 466 | 3 498 480 | |
2013-03-08 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 19 494 | 133 451 | 17,11 | 12,16 | 237 047 | 1 622 764 | |
2013-03-08 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −682 | 113 957 | −0,59 | 30,70 | −20 937 | 3 498 480 | |
2013-03-08 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 682 | 114 639 | 0,60 | 11,09 | 7 563 | 1 271 347 | |
2013-03-08 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −29 542 | 113 957 | −20,59 | 30,78 | −909 303 | 3 507 596 | |
2012-11-09 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
M - Exercise | −417 | 0 | −100,00 | ||||
2012-11-09 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
M - Exercise | −72 320 | 0 | −100,00 | ||||
2012-11-09 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 417 | 143 499 | 0,29 | 5,63 | 2 348 | 807 899 | |
2012-11-09 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 72 320 | 143 082 | 102,20 | 5,20 | 376 064 | 744 026 | |
2012-09-07 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −50 000 | 23 952 | −67,61 | ||||
2012-09-07 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −50 000 | 70 762 | −41,40 | 28,97 | −1 448 500 | 2 049 975 |
2012-09-07 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 50 000 | 120 762 | 70,66 | 12,16 | 608 000 | 1 468 466 | |
2012-09-07 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −2 825 | 73 952 | −3,68 | ||||
2012-09-07 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −42 175 | 682 | −98,41 | ||||
2012-09-07 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −2 825 | 70 762 | −3,84 | 27,97 | −79 015 | 1 979 213 |
2012-09-07 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 2 825 | 73 587 | 3,99 | 12,16 | 34 352 | 894 818 | |
2012-09-07 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −42 175 | 70 762 | −37,34 | 27,97 | −1 179 635 | 1 979 213 |
2012-09-07 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 42 175 | 112 937 | 59,60 | 11,09 | 467 721 | 1 252 471 | |
2012-08-27 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −13 126 | 42 857 | −23,45 | ||||
2012-08-27 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −17 874 | 0 | −100,00 | ||||
2012-08-27 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −13 126 | 70 762 | −15,65 | 26,97 | −354 008 | 1 908 451 |
2012-08-27 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 13 126 | 83 888 | 18,55 | 11,09 | 145 567 | 930 318 | |
2012-08-27 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −17 874 | 70 762 | −20,17 | 26,97 | −482 062 | 1 908 451 |
2012-08-27 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 17 874 | 88 636 | 25,26 | 10,29 | 183 923 | 912 064 | |
2012-08-27 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −14 000 | 17 874 | −43,92 | ||||
2012-08-27 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −14 000 | 70 762 | −16,52 | 26,97 | −377 580 | 1 908 451 |
2012-08-27 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 14 000 | 84 762 | 19,78 | 10,29 | 144 060 | 872 201 | |
2012-08-22 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 46 169 | 46 169 | 26,10 | 1 205 011 | 1 205 011 | ||
2012-08-22 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
A - Award | 3 831 | 3 831 | 26,10 | 99 989 | 99 989 | ||
2012-08-22 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 20 000 | 70 762 | 39,40 | ||||
2012-08-20 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −40 000 | 31 874 | −55,65 | ||||
2012-08-20 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −40 000 | 50 762 | −44,07 | 25,97 | −1 038 800 | 1 318 289 |
2012-08-20 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 40 000 | 90 762 | 78,80 | 10,29 | 411 600 | 933 941 | |
2012-06-14 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −19 583 | 0 | −100,00 | ||||
2012-06-14 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −30 417 | 0 | −100,00 | ||||
2012-06-14 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −19 583 | 50 762 | −27,84 | 24,97 | −488 988 | 1 267 527 |
2012-06-14 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 19 583 | 70 345 | 38,58 | 5,63 | 110 252 | 396 042 | |
2012-06-14 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −30 417 | 50 762 | −37,47 | 24,97 | −759 512 | 1 267 527 |
2012-06-14 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 30 417 | 81 179 | 59,92 | 5,20 | 158 168 | 422 131 | |
2012-06-14 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −45 000 | 30 417 | −59,67 | ||||
2012-06-14 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −45 000 | 50 762 | −46,99 | 23,97 | −1 078 785 | 1 216 917 |
2012-06-14 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 45 000 | 95 762 | 88,65 | 5,20 | 234 000 | 497 962 | |
2012-06-08 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −35 000 | 75 417 | −31,70 | ||||
2012-06-08 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −35 000 | 50 762 | −40,81 | 22,97 | −803 950 | 1 166 003 |
2012-06-08 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 35 000 | 85 762 | 68,95 | 5,20 | 182 000 | 445 962 | |
2006-02-01 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 19 583 | 19 583 | 5,63 | 110 252 | 110 252 | ||
2006-02-01 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
A - Award | 417 | 417 | 5,63 | 2 348 | 2 348 |